Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Science Translational Medicine Année : 2010

Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.

Résumé

The identification of one mechanism that causes vision loss in inherited degenerative retinal disorders revealed a new signaling molecule that represents a potential therapy for these currently untreatable diseases. This protein, called rod-derived cone viability factor (RdCVF), maintains the function and consequently the viability of cone photoreceptor cells in the retina; mice that lack this factor exhibit a progressive loss of photoreceptor cells. The gene encoding RdCVF also encodes, by differential splicing, a second product that has characteristics of a thioredoxin-like enzyme and protects both photoreceptor cells and, more specifically, its interacting protein partner, the tau protein, against oxidative damage. This signaling pathway potentially links environmental insults to an endogenous neuroprotective response.

Domaines

Génétique
Fichier principal
Vignette du fichier
inserm-00472434_edited.pdf (348.9 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-00472434 , version 1 (12-04-2010)

Identifiants

Citer

Thierry Léveillard, José-Alain Sahel. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.. Science Translational Medicine, 2010, 2 (26), 26ps16. ⟨10.1126/scitranslmed.3000866⟩. ⟨inserm-00472434⟩
154 Consultations
670 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More